文献速递消化道肿瘤与早癌

在KRAS突变结直肠癌细胞中,SLC25A22介导的谷氨酰胺分解减少DNA去甲基化从而增强WNT信号、干性和耐药

In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
PubMed 文献 · Gastroenterology · 2020-08-16

研究在ApcminKrasG12D小鼠及多种KRAS突变结直肠癌细胞中探讨SLC25A22介导的谷氨酰胺分解对表观遗传和细胞功能的影响,发现该通路通过增加琥珀酸积累导致DNA高甲基化,抑制protocadherin基因而激活WNT/β-catenin和LGR5,促进增殖、干性和5-氟尿嘧啶耐药;SLC25A22敲除减少小鼠肠肿瘤数量并降低类器官干性。

要点

  • KRAS突变结直肠癌细胞依赖SLC25A22进行谷氨酰胺分解,维持低α-酮戊二酸/琥珀酸比值。
  • SLC25A22介导的琥珀酸积累导致DNA高甲基化,沉默protocadherin基因,激活WNT/β-catenin和LGR5。
  • SLC25A22敲除减少ApcminKrasG12D小鼠肠肿瘤数量并增加5-氟尿嘧啶敏感性。

核心结论

  • 在表达活化KRAS的结直肠癌细胞中,SLC25A22促进琥珀酸积累,导致DNA甲基化增加、WNT/β-catenin信号激活、LGR5表达升高、增殖、干性特征及5-氟尿嘧啶耐药。
  • 原文指出针对该通路的策略可能被开发用于结直肠癌治疗。

研究设计与样本

  • 研究使用肠道特异性敲除SLC25A22的ApcminKrasG12D小鼠(ApcminKrasG12DSLC25A22fl/fl)及来自2例人结直肠肿瘤标本的类器官。
  • 体外使用表达突变KRAS的结肠上皮细胞(1CT)和结直肠癌细胞(DLD1、DKS8、HKE3、HCT116),进行谷氨酰胺或葡萄糖剥夺及SLC25A22等蛋白敲低或敲除。
  • 对来自香港130例患者的结直肠肿瘤样本(57例KRAS突变)进行免疫组化分析和Kaplan-Meier生存分析,并分析癌症基因组图谱中结直肠肿瘤的基因表达。

主要发现

  • 表达活化KRAS的结直肠癌细胞需要谷氨酰胺生存并快速将其纳入三羧酸循环,该过程需要SLC25A22;补充琥珀酸和非必需氨基酸可使细胞在无谷氨酰胺条件下增殖。
  • 突变KRAS细胞维持低α-酮戊二酸/琥珀酸比值,导致5-羟甲基胞嘧啶减少和CpG位点高甲基化,许多高甲基化基因位于WNT信号通路和染色体5q31的protocadherin基因簇。
  • 无突变KRAS或突变KRAS且敲除SLC25A22的结直肠癌细胞表达protocadherin基因(PCDHAC2、PCDHB7、PCDHB15、PCDHGA1、PCDHGA6),这些位点DNA未甲基化;protocadherin基因表达降低WNT/β-catenin信号和干细胞标志物LGR5表达。
  • ApcminKrasG12DSLC25A22fl/fl小鼠结肠肿瘤数量少于ApcminKrasG12D小鼠(P < .01);其类器官LGR5和其他干性标志物表达降低。
  • 在人结直肠肿瘤类器官中敲低SLC25A22降低克隆形成能力;敲低赖氨酸去甲基化酶或补充琥珀酸可恢复SLC25A22敲除结直肠癌细胞的LGR5表达;敲除SLC25A22增加突变KRAS结直肠癌细胞对5-氟尿嘧啶的敏感性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Mutant KRAS promotes glutaminolysis, a process that uses steps from the tricarboxylic cycle to convert glutamine to α-ketoglutarate and other molecules via glutaminase and SLC25A22. This results in inhibition of demethylases and epigenetic alterations in cells that increase proliferation and stem cell features. We investigated whether mutant KRAS-mediated glutaminolysis affects the epigenomes and activities of colorectal cancer (CRC) cells. METHODS: We created ApcminKrasG12D mice with intestine-specific knockout of SLC25A22 (ApcminKrasG12DSLC25A22fl/fl mice). Intestine tissues were collected and analyzed by histology, immunohistochemistry, and DNA methylation assays; organoids were derived and studied for stem cell features, along with organoids derived from 2 human colorectal tumor specimens. Colon epithelial cells (1CT) and CRC cells (DLD1, DKS8, HKE3, and HCT116) that expressed mutant KRAS, with or without knockdown of SLC25A22 or other proteins, were deprived of glutamine or glucose and assayed for proliferation, colony formation, glucose or glutamine consumption, and apoptosis; gene expression patterns were analyzed by RNA sequencing, proteins by immunoblots, and metabolites by liquid chromatography-mass spectrometry, with [U-13C5]-glutamine as a tracer. Cells and organoids with knocked down, knocked out, or overexpressed proteins were analyzed for DNA methylation at CpG sites using arrays. We performed immunohistochemical analyses of colorectal tumor samples from 130 patients in Hong Kong (57 with KRAS mutations) and Kaplan-Meier analyses of survival. We analyzed gene expression levels of colorectal tumor samples in The Cancer Genome Atlas. RESULTS: CRC cells that express activated KRAS required glutamine for survival, and rapidly incorporated it into the tricarboxylic cycle (glutaminolysis); this process required SLC25A22. Cells incubated with succinate and non-essential amino acids could proliferate under glutamine-free conditions. Mutant KRAS cells maintained a low ratio of α-ketoglutarate to succinate, resulting in reduced 5-hydroxymethylcytosine-a marker of DNA demethylation, and hypermethylation at CpG sites. Many of the hypermethylated genes were in the WNT signaling pathway and at the protocadherin gene cluster on chromosome 5q31. CRC cells without mutant KRAS, or with mutant KRAS and knockout of SLC25A22, expressed protocadherin genes (PCDHAC2, PCDHB7, PCDHB15, PCDHGA1, and PCDHGA6)-DNA was not methylated at these loci. Expression of the protocadherin genes reduced WNT signaling to β-catenin and expression of the stem cell marker LGR5. ApcminKrasG12DSLC25A22fl/fl mice developed fewer colon tumors than ApcminKrasG12D mice (P < .01). Organoids from ApcminKrasG12DSLC25A22fl/fl mice had reduced expression of LGR5 and other markers of stemness compared with organoids derived from ApcminKrasG12D mice. Knockdown of SLC25A22 in human colorectal tumor organoids reduced clonogenicity. Knockdown of lysine demethylases, or succinate supplementation, restored expression of LGR5 to SLC25A22-knockout CRC cells. Knockout of SLC25A22 in CRC cells that express mutant KRAS increased their sensitivity to 5-fluorouacil. Level of SLC25A22 correlated with levels of LGR5, nuclear β-catenin, and a stem cell-associated gene expression pattern in human colorectal tumors with mutations in KRAS and reduced survival times of patients. CONCLUSIONS: In CRC cells that express activated KRAS, SLC25A22 promotes accumulation of succinate, resulting in increased DNA methylation, activation of WNT signaling to β-catenin, increased expression of LGR5, proliferation, stem cell features, and resistance to 5-fluorouacil. Strategies to disrupt this pathway might be developed for treatment of CRC.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Wong CC, Xu J, Bian X, et al. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance. Gastroenterology. 2020. PMID: 32814111. doi:10.1053/j.gastro.2020.08.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。